SCHEMBL13289307

SCHEMBL13289307

Bc1cnn2c(NCCCN(C)C(=O)c3ccc4ccccc4c3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 5/20 0.41
▸ CDK2 P24941 5/20 0.41
▸ CXCR3 P49682 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ NPSR1 Q6W5P4 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ GFER P55789 1/20 0.37
▸ CCR6 P51684 1/20 0.36
▸ OPRM1 P35372 1/20 0.35
▸ TMEM97 Q5BJF2 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.35
▸ CCNE1 P24864 1/20 0.34
▸ PDE2A O00408 2/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ CTSG P08311 1/20 0.34
▸ CSNK2A1 P68400 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13288758 0.92 KDM4E (0.42) GSK3BCDK2CXCR3KDM4EMAPT
SCHEMBL13120405 0.91 GSK3B (0.54) GSK3BCDK2CXCR3KDM4EMAPT
SCHEMBL13288834 0.90 GSK3B (0.42) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13288912 0.89 GSK3B (0.43) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13288966 0.88 GSK3B (0.40) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13288933 0.88 RAB9A (0.41) GSK3BCDK2MAPTRAB9ARET
SCHEMBL13289036 0.88 ALDH1A1 (0.40) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13288863 0.88 CSNK2A1 (0.39) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13288756 0.88 GSK3B (0.40) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13288925 0.87 CDK2 (0.39) GSK3BCDK2KDM4EMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback